573 related articles for article (PubMed ID: 21218606)
1. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
4. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
8. Current options for the management of rectal cancer.
O'Neil BH; Tepper JE
Curr Treat Options Oncol; 2007 Oct; 8(5):331-8. PubMed ID: 18181024
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Glynne-Jones R; Mawdsley S; Harrison M
Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
[TBL] [Abstract][Full Text] [Related]
10. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
[TBL] [Abstract][Full Text] [Related]
11. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Créhange G; Bosset JF; Maingon P
Cancer Radiother; 2011 Oct; 15(6-7):440-4. PubMed ID: 21802334
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
[TBL] [Abstract][Full Text] [Related]
14. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Glynne-Jones R; Counsell N; Quirke P; Mortensen N; Maraveyas A; Meadows HM; Ledermann J; Sebag-Montefiore D
Ann Oncol; 2014 Jul; 25(7):1356-1362. PubMed ID: 24718885
[TBL] [Abstract][Full Text] [Related]
15. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Bullarddunn K; Yang GY; Pendyala L; Toth K; Andrews C; Rustum YM; Ross ME; Levea C; Puthillath A; Park YM; Rajput A
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):650-7. PubMed ID: 18565686
[TBL] [Abstract][Full Text] [Related]
19. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy and rectal cancer].
Michel P; Di Fiore F
Cancer Radiother; 2011 Oct; 15(6-7):436-9. PubMed ID: 21885319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
